Happy Thursday!
If you've been confused about what's going on with peptides and the government, you're not alone. A lot has happened this week, and what just dropped this week could change everything.
Today, I'm going to walk you through how we got here, what just happened, and what I think comes next for all of us in the peptide world.
This will be a longer email, so hopefully you have 5-10 minutes set aside to read the whole thing.
How We Got Here
To understand what's happening right now, you need to understand how peptides have been regulated up to this point.
Peptides are short chains of amino acids, many of which occur naturally in your body. Researchers have been studying them for decades for things like healing, inflammation, brain health, sleep, and body composition.
For years, there were two main ways people accessed peptides.
The first way was through a doctor. Your physician would write a prescription. A compounding pharmacy would make the peptide for you.
A compounding pharmacy is different from a regular pharmacy. Instead of dispensing mass-produced drugs off a shelf, they custom-make medications for individual patients. This is legal, regulated, and it's been around for a long time.
The legal framework that enables this is Section 503A of the Federal Food, Drug, and Cosmetic Act.
In simple terms, it says compounding pharmacies can make custom medications using certain approved ingredients as long as a doctor writes a prescription.
The second way people like us accessed peptides was through the research market. Companies sell peptides labeled "for research purposes only" or "not for human consumption."
For a while, both pathways coexisted. Doctors prescribed peptides through compounding pharmacies. People also bought them from research vendors. It wasn't perfect, but it worked.
And for the record, I support both sides of this. I always have.
The clinical world gives people medical oversight, quality control, and a doctor monitoring their health. The research world gave people access when the clinical world couldn't or wouldn't. Both pathways have helped real people get real results. I don't think you have to pick a team here.
But now, things are changing.
The Biden Administration
The FDA has had a category system since 2017 to classify bulk drug substances nominated for compounding.
But under the Biden administration, the FDA placed the most popular peptides into the worst category.
Category 1 meant "under evaluation." Compounding pharmacies could still work with these substances without too much trouble.
Category 3 meant "nominated without adequate support." The nominations lacked sufficient evidence.
Category 2 was the problem. It meant "bulk drug substances that raise significant safety concerns."
The FDA placed a long list of popular peptides into Category 2. These included most of the popular peptides we all know and love.
The Category 2 label didn't make these peptides illegal, but it made life extremely difficult for compounding pharmacies that wanted to make them.
The scrutiny went way up. The risk went way up. A lot of pharmacies stopped compounding them entirely because it just wasn't worth the regulatory headache.
Which meant your doctor couldn't easily prescribe them either. Even if your HRT doc or wellness provider wanted to write you a script for BPC-157, there was no easy way for a pharmacy to fill it.
That created a vacuum. And the research peptide market rushed in to fill it.
Over the last few years, the gray market has exploded.
Research peptide companies became the primary way most people accessed these compounds.
This left us in a weird middle ground where the clinical pathway was choked off, and the research pathway was the only practical option.
What Just Happened
Two documents dropped in the last 48 hours.
Document one came out yesterday, April 15. The FDA updated its 503A Categories list and announced that it's removing all of the following peptides from Category 2:
BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon, GHK-Cu (injectable), LL-37, Dihexa, PEG-MGF, and Melanotan II.
Document two came out today, April 16. The FDA published a Federal Register notice announcing a formal meeting of the Pharmacy Compounding Advisory Committee (PCAC). The meeting is scheduled for July 23-24, 2026, at the FDA's White Oak Campus in Silver Spring, Maryland.
At that meeting, the Committee will review seven of those twelve peptides for potential inclusion on the 503A Bulk Drug Substances List.
Here's what's on the July agenda:
July 23:
BPC-157 — being evaluated for ulcerative colitis
KPV — being evaluated for wound healing and inflammatory conditions
TB-500 — being evaluated for wound healing
MOTS-c — being evaluated for obesity and osteoporosis
July 24:
DSIP — being evaluated for opioid withdrawal, chronic insomnia, and narcolepsy
Semax — being evaluated for cerebral ischemia, migraine, and trigeminal neuralgia
Epitalon — being evaluated for insomnia
The remaining five (GHK-Cu, LL-37, Dihexa, PEG-MGF, and Melanotan II) are scheduled for PCAC review before the end of February 2027.
Practical Implications
These peptides are NOT becoming FDA-approved drugs.
The FDA is considering whether compounding pharmacies should be allowed to make these peptides without the regulatory cloud that's hung over them for the past few years.
If the PCAC recommends them for the 503A list, compounding pharmacies can manufacture them openly.
Doctors can prescribe them without worrying about their pharmacy getting shut down.
And patients can access them through a legitimate clinical pathway.
Think of it this way. The door to getting peptides from your doctor has been mostly closed. This process could reopen it.
My Predictions
I'm not a wizard, nor can I tell you exactly how this plays out. But here's my best guess.
Peptides will become more accessible through clinics. The providers that move first will be the ones already in this space. Your med spas, wellness clinics, and TRT clinic, etc. These are the doctors and practices that already understand peptides and already have patients asking about them. Once the regulatory pressure lifts, they'll start offering peptides pretty quickly.
Prices will start high but come down. At first, getting peptides through your doctor will probably cost more than what you're paying on the research side. That's just how it works in the beginning.
However, these peptides are not going to be patented drugs. They're compounded substances. When you have open competition and rising supply, prices fall. That's just how markets work.
Eventually, I think the cost of getting peptides from a clinic will come down to roughly what the research market charges now. Maybe not identical, but close enough that the difference stops mattering.
The economic incentives will shift. When you can get a quality-controlled peptide from your doctor for roughly the same price as ordering from a research vendor, most people are going to choose the doctor.
Think about metformin. Metformin is so easy and affordable to get from a doctor that most people just don't have a reason to source it from a research company. The prescription pathway is simple and cheap. I think the same thing eventually happens with peptides. The incentive to go the research route fades as the clinical route becomes just as easy and affordable.
Research peptides aren't disappearing overnight.
If you're someone who buys research peptides right now, I understand why this news might make you nervous. You're wondering if the FDA is about to shut down the vendors you rely on. You're wondering if this is the beginning of the end for your access.
Well, here’s what I think.
The gray market is pretty entrenched right now. Many people buy research peptides. A lot of companies sell them. That infrastructure has been built over the years. It doesn't just vanish because the FDA schedules a meeting.
Research peptides existed before Category 2. They existed during Category 2. And they'll exist after Category 2.
Will it get harder over time? Probably.
It might be harder to find certain peptides from research companies. You might have to use alternative payment methods. You might need to be in private groups where people share what's available and who's reliable. It'll be one of those whack-a-mole situations. Harder to navigate, but not impossible.
Honestly, I think both worlds will coexist for a while.
Some people will prefer the clinical route. Some will prefer the research route. Some will use both depending on the compound. That's fine. I'm not here to tell anyone which path to take. I support people having options.
What I don't think happens is some overnight collapse where you wake up and can't find BPC-157 from a research vendor. The shift will be gradual.
The tipping point comes when the clinical pathway is so easy and so affordable that buying research peptides just doesn't make practical sense for most people anymore.
When your doctor can prescribe it for roughly the same cost, most people will choose that route. It's just basic economics.
Until that tipping point arrives, the research market will keep doing what it does.
And I'll keep supporting everyone in this community regardless of how they access their peptides.
How You Can Get Involved
The FDA opened a public docket for the July meeting. That means you can submit comments that real people at the FDA will actually read.
Anyone can submit a comment about peptides at: https://www.regulations.gov/document/FDA-2025-N-6895-0001
Key dates:
June 30, 2026 — Deadline to request to speak at the meeting.
July 9, 2026 — Deadline for written comments to reach Committee members before the meeting.
July 22, 2026 — Final deadline for all comments.
If you've participated in the Peptide Safety Initiative, this is the moment that data was designed for.
The FDA wants to know if these compounds are safe enough for compounding.
They will be evaluating our data at the meeting.
Final Thoughts
At the end of the day, I'm in favor of what's happening here. And I'm still in your corner regardless of how you access peptides.
More people having access to more peptides is a good thing.
The Category 2 designation choked off the clinical pathway and pushed people toward the gray market. Removing that bottleneck and giving these compounds a real regulatory review is a step in the right direction.
If you get your peptides from a doctor, this is great news. Your pathway is about to get a lot cleaner.
If you get your peptides from the research market, don't panic. This isn't the end of anything. It's the beginning of a transition that will play out over months and years.
Peptides are becoming more accessible, more normalized, and the clinical pathway is opening up.
Eventually, the economics will align so that most people can get what they need through a provider they trust at a price that makes sense.
That's a good outcome for everyone.
I'll be tracking this closely and keeping you updated along the way!
Stay tuned.
Best,
Hunter Williams